Guardant Health, Inc.: Guardant Health and The Royal Marsden

Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual

Related Keywords

United Kingdom , Helmy Eltoukhy , Alex Kleban , David Cunningham , Guardant Health , National Institute Of Health Research , Linkedin , Twitter , Nasdaq , Exchange Commission , Guardant Health Inc , Guardant Health Contacts , Guardant Health Forward , Institute Of Cancer Research , Royal Marsden Cancer Charity , Research Council , Foundation Trust On Part , Guardant Reveal , Royal Marsden , Arly Colorectal , Professor David Cunningham , Mechanism Evaluation , Medical Research Council , National Institute , Health Research , Cancer Research , Health Research Biomedical Centre , Financial Condition , Annual Report , Cancer Res , Health Contacts , Guardant , Health , Royal , Marsden , Foundation , Trust , Partner , Ighly , Nticipated , Tracc , Art , Trial , Reveal , Flood , Pest , Help , Uide , Treatment , Decisions , Olorectal , Dancer ,